To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

This study is testing furmonertinib, a targeted oral drug, as a treatment after surgery for early-to-intermediate stage non-small cell lung cancer in patients whose tumor has a specific genetic change (EGFR exon 20 insertion mutation). **You may be eligible if...** - You are 18 or older - You had complete surgical removal of your lung cancer (all cancer removed, clear margins) - Your tumor is confirmed to have an EGFR exon 20 insertion mutation - Your cancer was classified after surgery as stage IB, II, or IIIA - You have fully recovered from surgery and any adjuvant chemotherapy - Your general health is good (ECOG 0–1) **You may NOT be eligible if...** - You only had a small partial lung removal (wedge or segmentectomy — a full lobe must have been removed) - You received any prior cancer treatment other than adjuvant platinum-based chemotherapy - You are taking medications that strongly affect a liver enzyme called CYP3A4 - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.